Defects in the apoptotic signaling cascades contribute to the poor therapeutic response of malignant gliomas. As glioblastomas are characterized by high expression levels of anti-apoptotic Bcl-2 family proteins, we studied the effects of the novel Bcl-2 inhibitor, ABT-737, on malignant glioma cells. ABT-737 treatment released the pro-apoptotic Bax protein from its binding partner Bcl-2 and potently induced apoptotic cell death in glioblastoma cells in vitro and in vivo. The local administration of ABT-737 prolonged the survival in an intracranial glioma xenograft model. Downregulation of Mcl-1 and overexpression of Bcl-2 sensitized the cells to ABT-737-mediated apoptosis. Moreover, ABT-737 potentiated the cytotoxicity of the chemotherapeutic drugs vincristine and etoposide, and of the death ligand TRAIL. As glioma stem cells may play a crucial role for the tumor progression and the resistance to treatment in glioblastomas, we investigated the effects of ABT-737 on the subpopulation of glioma cells exhibiting stem cell characteristics. Inhibition of proliferation and induction of apoptosis by ABT-737 were less efficient in glioma stem cells than in non-stem cell-like glioma cells. As the resistance of glioma stem cells was associated with high Mcl-1 expression levels, ABT-737 treatment combined with downregulation of Mcl-1 could represent a promising novel approach in glioblastoma treatment.
Introduction
Defects in the apoptotic cell death program contribute to the intrinsic resistance of tumor cells to anticancer therapy. Glioblastomas, the most common and most malignant brain tumors in adulthood, are often resistant to radiotherapy as well as to chemotherapeutic agents. The median survival time of patients suffering from these tumors is only 14 months after primary diagnosis. One major cause of the resistance to apoptosis in malignant glioma cells is the overexpression of antiapoptotic proteins, including Bcl-2, Bcl-XL, Mcl-1, IAPs, AKT and others (Krajewski et al., 1997; Wagenknecht et al., 1999; Kraus et al., 2001; Riemenschneider et al., 2006) . There is ample evidence that the family of Bcl-2-related antiapoptotic proteins plays an important role in glioma cell resistance. Bcl-2 confers radio-and chemoresistance to glioma cells (Weller et al., 1995; Del Bufalo et al., 2001) and promotes the intracranial growth of glioma xenografts (Weiler et al., 2006) . Similarly, Bcl-XL was shown to confer resistance to chemotherapeutic drugs in glioblastoma cells (Nagane et al., 1998) . Therefore, targeting Bcl-2 family proteins seems to be a promising therapeutic strategy to combat brain cancer. Several preclinical and clinical trials are underway to evaluate the therapeutic efficacy of Bcl-2 family inhibitors in patients with glioblastomas or other malignancies (Tse et al., 2008 ; for review, see Reed, 2006 and http://www.cancer.gov/clinicaltrials/).
Recently, the development and preclinical testing of a novel small molecule inhibitor, ABT-737, sparked new hopes for a successful Bcl-2 family inhibitor-based treatment of cancer (Oltersdorf et al., 2005) . ABT-737 shows high affinity to Bcl-2, Bcl-XL and Bcl-w and exhibits potent antitumor activity as a single agent treatment for several types of cancer (Oltersdorf et al., 2005; Konopleva et al., 2006; van Delft et al., 2006; Chauhan et al., 2007; Chen et al., 2007; Del Gaizo Moore et al., 2008; Tahir et al., 2007; Trudel et al., 2007; Hann et al., 2008) . However, a study on the antitumoral efficiency of ABT-737 in malignant gliomas has not been published so far. Here, we describe that ABT-737 potently induces apoptosis in glioblastoma cells and that ABT-737 sensitizes the cells to anticancer drugs and to the death ligand TRAIL. We also describe the effects of ABT-737 on stem cell-like glioma cells, as there is mounting evidence that these cells play a pivotal role in the evolution of malignant brain tumors. The so-called 'glioma stem cells' might represent the cellular origin of malignant gliomas and they may promote the progression of astrocytomas and oligodendrogliomas to glioblastomas (Sanai et al., 2005) . Moreover, it is believed that the subgroup of glioma cells with stem cell characteristics essentially contributes to the radio-and chemoresistance of gliomas, resulting in an early relapse of the tumor after therapy (Bao et al., 2006; Stupp and Hegi, 2007) . Therefore, the success of novel therapeutic approaches for glioblastomas might depend on their ability to target the stem cell-like glioma cells.
Results

Pro-apoptotic activity of ABT-737 in glioblastoma cells: regulation by Mcl-1
The acute cytotoxicity of ABT-737 was determined in a panel of long-term cultured cell lines (U87MG, U251MG) and ex vivo glioma cell cultures with a low number of passages (NCH89, NCH156). The EC 50 values of ABT-737 were in the low micromolar concentration range in ex vivo glioma cell cultures, whereas long-term cultured cell lines required moderately higher ABT-737 concentrations to achieve 50% cell killing (Figure 1a) . To investigate the possible NCH89 and NCH156 glioblastoma cells were incubated with the indicated ABT-737 concentrations for 24 h. Then, whole cellular lysates were generated and subjected to immunoblot analysis for full length (p32) and cleaved caspase 3 (p19/p17). Lower panel: glioma cells were treated as described above. Cleavage of PARP was detected by immunoblotting. Actin served as a loading control. (c) Expression of Bcl-2, Mcl-1, and Bax proteins in ABT-737-resistant (1, resistant to 10 mM ABT-737; 2, resistant to 20 mM ABT-737) and control NCH89 glioma cells (upper panel). Resistance to ABT-737 is demonstrated by FACS analysis of the apoptotic (sub-G 1 ) cell fraction after a 24 h incubation period with ABT-737 (lower panel; ±s.d.; student's t-test, n ¼ 3; *Po0.001, compared with control). (d) Downregulation of endogenous Mcl-1 by siRNA results in sensitization to ABT-737. Twenty-four hours after transfection of siRNA, the glioma cells were incubated with ABT-737 for 24 h (NCH89, 2 mM; U87MG, 50 mM; U251MG, 20 mM). The percentage of apoptotic cells was determined by FACS analysis (upper panel). Data represent the mean of three independent experiments ( ± s.d., student's t-test; n ¼ 3: *Po0.05; **Po0.001). Successful knockdown of Mcl-1 was monitored by generating cellular lysates 24 h after transfection and subsequent immunoblot analysis for Mcl-1 expression (lower panel).
reasons for the differential susceptibility to ABT-737 in various cell lines, we examined the expression levels of diverse antiapoptotic proteins. Interestingly, the most sensitive cell line, NCH156, was characterized by high Bcl-2 and low Mcl-1 expression, whereas the least sensitive cell line, U87MG, reciprocally showed low Bcl-2 and high Mcl-1 expression levels ( Figure 1a , lower panel). ABT-737-induced cell death showed the typical characteristics of apoptosis, such as cleavage of caspase3 and of the caspase substrate PARP (Figure 1b) , and the morphological signs of apoptosis, that is, nuclear condensation and fragmentation as well as cytoplasmic blebbing (not shown). Next, we generated ABT-737-resistant glioblastoma cells by prolonged incubation with increasing concentrations of ABT-737. After 8 weeks, the ABT-737-resistant cells showed strongly upregulated expression levels of Mcl-1 as well as downregulated Bcl-2 expression ( Figure 1c) . As the role of Mcl-1 in the resistance to ABT-737 is well established (Lin et al., 2006; van Delft et al., 2006; Chen et al., 2007; Del Gaizo Moore et al., 2007; Kang et al., 2008) , we tested whether a decrease of Mcl-1 would sensitize glioblastoma cells to ABT-737. In fact, siRNAmediated downregulation of Mcl-1 resulted in a potent sensitization to ABT-737-induced apoptosis (Figure 1d ).
Treatment of subcutaneous and intracerebral glioblastoma xenografts with ABT-737
To investigate whether ABT-737 induces apoptosis not only in monolayer cultures in vitro, but also in threedimensional solid tumors in vivo, we treated mice bearing subcutaneous U251MG glioma xenografts with systemic (i.p.) injections of ABT-737. In contrast to the controls where only minimal necrosis was seen, ABT-737-treated xenografts showed massive signs of cell death in approximately 40% of the tumor tissue as assessed in serial sections of the tumors. The cell death of glioma cells in vivo was at least partly because of the induction of apoptosis, as extensive activation of caspase 3 was detected by immunohistochemistry ( Figure 2a) . Next, we treated mice with established intracranial U251MG glioblastoma xenografts with two local injections of ABT-737 (7.5 mg/kg). No clinical abnormalities were observed after the two injections. Subsequently, the mice were observed at regular intervals. When the animals developed neurologic symptoms, they were killed and the time points were documented as depicted in Figure 2b . The median survival of the control-treated group was 62 days. All of the control animals and four of the ABT-737-treated mice developed symptoms because of intracranial tumor growth. In contrast, the remaining four ABT-737-treated U251MG cells were stereotactically implanted into the striatum of athymic mice. On days 7 and 9, the animals received an intratumoral injection of ABT-737 (7.5 mg/kg; n ¼ 8) or carrier solution (n ¼ 10). The animals were observed at regular intervals until they developed neurological symptoms. At the end of the observation period, the surviving animals (n ¼ 4; all in the ABT-737-treated group) were killed and the brains were examined histologically. In these four ABT-737-treated mice, residual tumor tissue was not detected. (c) Histological analysis of ABT-737-treated glioma xenografts. U251MG glioma cells were inoculated and treated with ABT-737 as described in (b). After 8 weeks, sections of the brain were examined by hematoxylin and eosin (H&E) staining and immunohistochemical detection of CD68 (microglia, macrophages) and GFAP (astrocytic cells) (magnifications: Â 60). T, tumor. Arrows: macrophages (right upper panel), reactive astrocytes (right lower panel). mice remained free of symptoms for the observation period of 90 days (P ¼ 0.028, Mantel-Haenszel log rank test). No residual glioma tissue was detected 90 days after tumor implantation in the brains of the four surviving ABT-737-treated mice. Next, we investigated the effects of an ABT-737 treatment on the local tumor growth. U251MG glioma xenografts were treated with two intratumoral ABT-737 injections (7.5 mg/kg). After 8 weeks the tumor tissue and the adjacent brain tissue were examined by histology and immunohistochemistry. Control-treated animals showed a solid tumor (T) growing in the basal ganglia ( Figure High Bcl-2 expression levels promote sensitivity to ABT-737-induced apoptosis Although there is ample evidence that Mcl-1 regulates the response to ABT-737 treatment, the role of Bcl-2 and survivin expression levels for sensitivity to ABT-737 are far from clear. Therefore, we generated glioma cells stably overexpressing Bcl-2 or survivin. ABT-737-induced cell death was significantly increased in the cells with high Bcl-2 expression, whereas ectopic expression of survivin did not alter cell survival after ABT-737 treatment ( Figure 3a ABT-737 efficiently releases Bax from the complex with Bcl-2 As the precise mechanisms of action of ABT-737-induced cell death are still unclear and might be cell type-dependent, we investigated the effects of ABT-737 on the interaction of Bax and Bad with Bcl-2. U251MG glioblastoma cells stably overexpressing Bcl-2 and, as a control for cell type specificity, transiently Bcl-2-transfected MCF-7 breast cancer cells were treated with ABT-737. Coimmunoprecipitation experiments demonstrated that ABT-737 efficiently prevented the binding of Bax to Bcl-2 in glioblastoma as well as in breast cancer cells (Figures 4a and b) . Although large amounts of endogenous Bax were bound to Bcl-2 in the absence of ABT-737, a complete loss of Bax in Bcl-2 immunoprecipitates was observed in the presence of ABT-737. Similar results were obtained for the Bad protein (Figures 4c and d) . However, the amount of Bad that was prebound to Bcl-2 was much lower when compared with Bax, as demonstrated by the ratio between endogenous expression levels in the lysate controls and the amount of Bad or Bax detected in Bcl-2 immunoprecipitates. This may also be because of the fact that the detergents in the cellular lysates used for coimmunoprecipitation are known to promote the association of Bax with Bcl-2, thereby possibly resulting in a stronger protein interaction as occurring physiologically in vivo. Nevertheless, ABT-737 treatment resulted in a complete displacement of Bad from Bcl-2.
ABT-737 sensitizes glioblastoma cells to cytotoxic drug-and death ligand-induced apoptosis Next, we investigated whether low concentrations of ABT-737 that are not sufficient to kill glioblastoma cells, would be able to sensitize them for apoptosis triggered by cytotoxic drugs or death ligands. Various glioblastoma cell lines were treated with ABT-737, vincristine, etoposide, or TRAIL, or the combinations thereof. To assess the efficacy of combination treatments, the theoretically expected additive effect of cotreatment was calculated and compared with the actually observed effect. In all cases, ABT-737 synergistically enhanced the cytotoxicity of the anticancer drugs as well as of the death ligand TRAIL (Figures 5a-c) . Moreover, the synergistic activity of cotreatments correlated with the enhanced cleavage of pro-apoptotic caspases, as demonstrated for caspase 3 cleavage after treatment with ABT-737 and etoposide (Figure 5d ).
Pro-apoptotic and antiproliferative activity of ABT-737 in stem cell-like glioblastoma cells Next, we compared the effects of ABT-737 in pairs of stem cell-like glioblastoma cells (SCG) and non-stem cell-like glioblastoma cells (N-SCG). Each pair of SCG and N-SCG cultures were derived from the same surgical glioblastoma sample. The generation and characteristics of these cell lines are described in detail elsewhere (Campos et al., 2008) . In brief, glioma cell cultures derived from surgically removed tumor tissue were either established in fetal calf serum-containing medium (N-SCG) or a medium optimized for the growth of normal neural stem cells containing bFGF, EGF and the serum-free supplement BIT9500 (SCG) (Dictus et al., 2007) . SCG cells displayed stem celltypical growth as neurospheres, increased expression of CD133 and nestin, and were highly tumorigenic after implantation in NOD/SCID mice. First, we treated the pairs of SCG and N-SCG cells with ABT-737 and assessed the proliferation rates over 3 days. N-SCG cells showed a significant decrease in proliferation, whereas SCG cells responded less to ABT-737 treatment ( Figure 6a) . Next, the pro-apoptotic activity of ABT-737 was determined by FACS analysis. Compared to N-SCG cells, the SCG cells were less susceptible to ABT-737-induced apoptosis (Figure 6b ). This finding was accompanied by a substantially decreased cleavage of caspase 3 in SCG after ABT-737 treatment ( Figure 6c ). As Bcl-2 and Mcl-1 levels regulate the 
Discussion
Pro-apoptotic stimuli lead to the activation of the BH3-only proteins which bind to and neutralize the antiapoptotic Bcl-2-like proteins (Adams et al., 2005) . Mediated by still not completely understood mechanisms, this results in aggregation of the Bax and Bak proteins at the mitochondria triggering the signaling cascade of mitochondrial apoptosis. Several models have been proposed for the interaction and activation of Bax and Bak. These models differ mainly regarding the question whether Bax/Bak are directly activated upon release from Bcl-2 or, alternatively, require additional activation by so-called 'activator' BH3-only proteins (reviewed in Green, 2006; Letai, 2006) . The precise roles of these 'activator' BH3-only proteins (Bim, Bid) compared with the 'sensitizer' BH3-only proteins (for example, Bad) are still a matter of debate. Increasing evidence suggests that the regulation of mitochondrial apoptosis and the requirement of specific activator and sensitizer BH3-only proteins may depend on the type of tissue and on the cellular context.
The small molecule inhibitor ABT-737 interferes directly with mitochondrial signaling events by high affinity binding to Bcl-2, Bcl-XL and Bcl-w (Oltersdorf et al., 2005; Certo et al., 2006) . Here we show, that glioblastoma cells are highly susceptible to ABT-737-induced apoptosis in vitro and in vivo. Similar to reports in other tumor entities, glioblastoma cells can be sensitized to ABT-737 by downregulating Mcl-1 which functions as a key negative regulator of ABT-737 susceptibility. In contrast, sensitivity to ABT-737 is not altered by ectopic expression of survivin, which is often found overexpressed in malignant gliomas (Kajiwara et al., 2003) . In addition, we provide evidence that the expression of Bcl-2 itself decisively regulates the response to ABT-737 treatment. The cytotoxic effects of ABT-737 correlate positively with the expression levels of Bcl-2. This finding is in accordance with a recent report demonstrating that the genomic amplification of the region containing Bcl-2 correlates with ABT-737 sensitivity in small-cell lung carcinoma (Olejniczak et al., 2007) . The fact that human malignant gliomas exhibit high Bcl-2 protein levels (Krajewski et al., 1997; Kraus et al., 2001) encourages the investigation of ABT-737 as a novel experimental drug for glioblastomas. What is the reason for the increased sensitivity to ABT-737 in cells with high Bcl-2 expression? Our results suggest that in glioblastoma cells large amounts of Bax protein are prebound to Bcl-2 and are acutely released by ABT-737 treatment. The more 'addicted' glioma cells become to the Bax-neutralizing Bcl-2 protein, the more sensitive they will be to a rapid release of Bax protein caused by its replacement by ABT-737. Alternatively, other BH3-containing proteins such as the 'activator' protein Bim may play a role in the regulation of sensitivity to ABT-737 in glioblastomas. Recently, Deng et al. (2007a) demonstrated that in lymphoma cells the sensitivity to ABT-737 correlates tightly with the abundance of Bcl-2 and Bcl-2/Bim protein complexes. This observation supports the hypothesis that the 'priming' of Bcl-2 with activator proteins determines Bcl-2 dependence and sensitivity to ABT-737.
We further show that locally administered ABT-737 prolongs the survival of nude mice bearing intracranial glioblastoma xenografts. As the locoregional application of cytotoxic drugs in glioblastoma patients is well established, the local delivery of ABT-737 might allow ) were treated with ABT-737 (10 mM) for 24 h or left untreated. After generation of lysates, immunoprecipitations (Co-IP) were performed using anti-Flag monoclonal antibodies, followed by SDS-PAGE/immunoblot analysis using antibodies specific for Bax (a, b) or Bad (c, d). As a control (last four lanes in a-c, first two lanes in d), an aliquot of the lysates was also loaded directly into gels and analysed by immunoblotting (lysates). To demonstrate equal expression of Bcl-2-Flag, immunoblot membranes were re-probed with an anti-Flag antibody (bottom panels).
the administration of higher ABT-737 dosages than those achievable by systemic treatment. Nevertheless, further detailed studies will have to address the potential local and systemic side effects of an ABT-737-based therapy. We observed macrophage infiltrates and astrogliosis in the adjacent brain tissue several weeks after injection of ABT-737, which might be the reaction to the resorption of necrotic tumor tissue. However, to exclude neurotoxic or pro-inflammatory side effects of ABT-737, a careful and comprehensive evaluation of the dose-dependent effects of ABT-737 on neurons, astrocytes and microglia is necessary. Interestingly, neurons have been reported to express only low levels of Mcl-1, but higher levels of Bcl-2 (Krajewski et al., 1995) . Although we did not observe neuronal loss after local ABT-737 treatment, the question has to be addressed whether low Mcl-1 and high Bcl-2 expression levels predispose human neuronal cells to the long-term sequela of an ABT-737-based therapy.
Malignant gliomas are heterogeneous tumors and not all glioblastoma cells may underlie the same regulation mechanisms for Bax-induced apoptosis. This is especially relevant in light of the ongoing discussion that the so-called 'glioma stem cells' constitute a functionally and therapeutically important subpopulation in glioblastomas. The glioma stem cells, like other cancer stem cells, are characterized by high tumorigenicity, selfrenewal and differentiation (Sanai et al., 2005) . Another important feature of cancer stem cells is their increased resistance to chemotherapeutic drugs and radiotherapy (Bao et al., 2006; Eramo et al., 2006 ) which makes them a major target for novel treatment strategies. Obviously, overexpression of anti-apoptotic proteins or downregulation of pro-apoptotic proteins could be important mechanisms of cancer stem cell resistance. Our experiments suggest that stem cell-like glioma cells are in fact more resistant to induction of apoptosis by ABT-737. Importantly, the glioma cells with stem cell features were characterized by high expression levels of Mcl-1 or, alternatively, low expression levels of Bax, when compared with their non-stem cell-like counterparts. As stem cell-like glioma cells are sensitized to ABT-737 by Mcl-1 downregulation, the high Mcl-1 expression levels in these cells may explain their increased resistance to ABT-737. Provided that Mcl-1 is a central regulator of ABT-737 sensitivity in these cells, a possible future ABT-737-based experimental treatment for glioblastoma should be combined with Mcl-1-lowering strategies (for example, Kang et al., 2008) to extend the therapeutic range to the glioma stem cell compartment.
Our findings further suggest that ABT-737 qualifies as a promising candidate for a combination therapy of malignant gliomas. Subtoxic concentrations of ABT-737 substantially sensitized glioblastoma cells to cell death induced by anticancer drugs. This finding is in accordance with synergistic effects of ABT-737 and cytotoxic drugs or EGFR inhibitors in other tumor entities, such as lung cancer, multiple myeloma and acute lymphoblastic leukemia (Oltersdorf et al., 2005; Chauhan et al., 2007; Cragg et al., 2007; Deng et al., 2007b; Gong et Data are presented as mean of three independent experiments (±s.d.; student's t-test; n ¼ 3; *Po0.05; **Po0.01; differences between the calculated (additive) and the observed effects of combination treatment). For determination of the calculated additive effect, see Materials and methods. The following concentrations were used: (a) TRAIL: 200 ng/ml, U87MG; 10 ng/ml, U251MG; 5 ng/ml, NCH89; ABT-737: 10 mM, U87MG; 10 mM, U251; 1 mM, NCH89. (b) Vincristine: 50 nM, U87MG; 0.1 nM, U251MG; 4 nM, NCH89; ABT-737: 10 mM, U87MG; 10 mM, U251; 10 mM, NCH89. (c) Etoposide: 25 mM, U87MG; 4 mM, U251MG; 5 mM, NCH89; ABT-737: 10 mM, U87MG; 10 mM, U251; 1 mM, NCH89. (d) ABT-737 and etoposide synergistically induces cleavage of caspase 3. NCH89 cells were treated with ABT-737 (1 mM) and etoposide (5 mM) for 24 h. Caspase 3 cleavage was determined by immunoblot analysis. Actin served as a loading control.
2007). Anticancer drugs, such as vincristine and etoposide, exert their cytotoxic effects at least partly through mitochondrial apoptosis pathways. Therefore, the observed synergy might be caused by an ABT-737-dependent decrease of the Bcl-2/Bcl-XL buffer systems for pro-apoptotic BH3-only proteins and Bax/Bak. Likewise, apoptosis induced by the TRAIL death ligand was significantly potentiated by ABT-737. Caspase 8-mediated apoptosis in glioblastoma cells is characterized by a Bid-dependent mitochondrial amplification loop Fulda et al., 2002a) . Sensitization of cancer cells to TRAIL has been reported through antagonization of Bcl-2 by siRNA-mediated downregulation or by the Bcl-2 inhibitor HA 14-1 as well as by ABT-737 (Zangemeister-Wittke, 2003; Chawla-Sarkar et al., 2004; Sinicrope et al., 2004; Huang and Sinicrope, 2008) . TRAIL is a promising experimental anticancer compound that is currently tested in clinical phase II trials (http://www.gene.com/). Moreover, preclinical studies suggest that TRAIL is highly effective in malignant gliomas (Roth et al., 1999; Nagane et al., 2000; Pollack et al., 2001; Fulda et al., 2002b) . However, a subpopulation of glioblastoma cells is resistant to TRAIL which may partly be caused by Bcl-2 overexpression (Rieger et al., 1998; Fulda et al., 2002a) . Therefore, a combination therapy of ABT-737 and TRAIL may constitute a potent apoptosis-based treatment strategy for malignant brain tumors with the potential to overcome TRAIL resistance.
Novel, high-affinity Bcl-2 inhibitors such as ABT-737 are a welcome addition to the available repertoire of experimental anticancer compounds in preclinical or clinical testing. Our study is the first to investigate the antitumoral activity of ABT-737 in glioblastomas, the most devastating and also most common malignant brain tumor. ABT-737 proves to be efficient against glioblastoma cells as a single agent as well as in combination with cytotoxic drugs and the death ligand TRAIL. High Bcl-2 expression levels responsible for the sequestration of relatively large amounts of Bax that can be acutely released by ABT-737 might make glioblastomas to an appropriate target for an ABT-737-based treatment strategy. A concomitant downregulation of Mcl-1 should be achieved to efficiently target the stem cell-like glioma cells.
Materials and methods
Materials
Etoposide and vincristine were purchased from Sigma (Deisenhofen, Germany). Soluble TRAIL was purchased from Biomol (Hamburg, Germany). The antibodies were obtained as follows: mouse monoclonal anti-caspase 3 antibody (Imgenex, San Diego, CA, USA); mouse monoclonal antiBcl-2 antibody, rabbit polyclonal anti-Bax, anti-Mcl-1 and anti-Bad antibodies (Santa Cruz, San Diego, CA, USA); mouse monoclonal anti-actin antibody (Chemicon, Ochsenhausen, Germany); mouse monoclonal anti-b-tubulin and mouse monoclonal anti-PARP antibody (BD Pharmingen, Heidelberg, Germany); mouse monoclonal anti-Flag antibody (Sigma). ABT-737 was provided by Abbott (Abbott Park, Illinois, IL, USA).
Cell culture and viability assays
The human glioma cell lines were cultured in DMEM containing 10% FCS, 1 mM glutamine, 25 mM glucose and 1% penicillin/streptomycin. Primary (ex vivo) glioma cell cultures and stem cell-like glioblastoma cells were established as described (Karcher et al., 2006; Campos et al., 2008) . For the generation of ABT-737 resistant cell lines, NCH89 glioblastoma cells were incubated with complete medium containing increasing concentrations of ABT-737 (0-20 mM) for 8 weeks. For acute cytotoxicity assays, 10 4 cells were plated in 96-well plates, adhered for 24 h, and exposed to ABT-737, TRAIL, vincristine or etoposide for 24 h. For a combined treatment of ABT-737 with either TRAIL, vincristine or etoposide, the cells were pretreated with ABT-737 for 1 h. The percentage of surviving cells was assessed by staining with crystal violet (Gillies et al., 1986) . Briefly, the supernatant was removed, and the cells were incubated in a 2% crystal violet solution in 20% methanol for 10 min. The plates were washed in running tap water and air-dried for 24 h. Crystal violet was solubilized by the addition of a 0.1 M sodium citrate buffer in 50% ethanol. The absorption was measured at 550 nm using a microplate reader (Bio-Rad Instruments, Munich, Germany). For acute cytotoxicity assays using NCH421k stem cell-like glioma cells, 1.5 Â 10 4 cells were plated in 96-well plates. Twenty-four hours later the cells were incubated with ABT-737 for additional 24 h. The percentage of surviving cells was determined by trypan blue exclusion assay. For the BrdUbased assessment of cellular proliferation, 3 Â 10 4 glioblastoma cells were plated in 96-well plates and exposed to ABT-737 for 48 h followed by BrdU labeling using the Cell Proliferation ELISA, BrdU colorimetric Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. Transfections were performed as outlined in Supplementary Information.
Synergy was evaluated by the fractional product method that allows an evaluation of synergy at a defined level of effect. In the fractional product method, the effect of two independently acting agents is defined as the product of the unaffected fractions after treatment with either drug alone: f u (1,2) ¼ f u (1) Â f u (2) (Webb, 1963) . This formula allows the predicted effect of cotreatment to be calculated on the basis of the assumption that the two agents do not interact or cooperate in inducing their effects. If the relative percentage of surviving cells after cotreatment with the two drugs is below the calculated product f u (1,2), then the two drugs show synergy.
FACS analysis
For cell cycle analysis, 6 Â 10 5 glioma cells per sample were treated as indicated, washed, incubated with trypsin for 3 min at 37 1C, harvested, washed and stained either with propidium iodine (20 mg/ml in Nicoletti buffer) or with Annexin V-PE (Apoptosis Detection Kit I, BD Pharmingen, Heidelberg, Germany) according to the manufacturer's instructions. Cells were subjected to flow cytometry analysis of DNA content using a Becton Dickinson FACScalibur cytometer and Cell Quest Software (BD Biosciences, Heidelberg, Germany).
siRNA-mediated Mcl-1 downregulation by lentiviral infection
To target the Mcl-1 protein for downregulation by siRNA we generated the pSUPER-Mcl-1 construct and, as a control, pSUPER-siRNA-control according to the manufacturer's instruction (OligoEngine, Seattle, WA, USA). For oligonucletide sequences, see Supplementary Information. The siRNA sequence including the H1 promotor was subcloned into the lentiviral expression vector pG-Lenti (kindly provided by Carol Stocking-Harbers, Hamburg, Germany), which expresses GFP under the control of the SFFV promoter. Amphotropic retroviral supernatants were produced by transient transfection of 293T cells with the retroviral packaging vectors pMDLg/pRRE, pRSV-Rev and pMD.G and the corresponding siRNA construct. NCH421k stem celllike glioma cells were infected once with retroviral supernatant. Successful infection was monitored by GFP expression and verified by immunoblot analysis of Mcl-1.
Coimmunoprecipitation U251MG glioma cells stably transfected with pcDNA3-Bcl-2-Flag or, as a control, the empty expression vector (neo) were seeded in 10 cm dishes (3 Â 10 6 cells per dish) and incubated in the presence or absence of ABT-737 (10 mM) for 24 h. Alternatively, MCF-7 cells were seeded in 10 cm dishes (4 Â 10 6 cells per dish) and transiently transfected with pcDNA3-Bcl-2-Flag plasmid (10 mg) or pcDNA3-neo (10 mg). Twenty-four hours post-transfection, cells were treated with ABT-737 (10 mM) for 24 h. Then, the cells were collected and resuspended in lysis buffer (30 mM Tris (pH 7.4), 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 10% glycerol, 1% Triton X-100) containing a protease inhibitor mixture (Roche Molecular Biochemicals, Hannheim, Germany). Soluble lysates were incubated with 10 ml anti-FLAG antibody M2-conjugated agarose (Sigma) at 4 1C for 12 h. After extensive washing, immune complexes were fractionated by SDS-Polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose for immunoblotting using monoclonal mouse anti-Flag, polyclonal rabbit anti-Bax or polyclonal rabbit anti-Bad antibodies, followed by horseradish peroxidase-conjugated antibodies. Immunoblot analysis was performed as outlined in Supplementary Information. An enhanced chemiluminescence system (GE-Healthcare) was used for detection.
Animal studies
All animal work was carried out in accordance with the NIH guidelines 'Guide for the Care and Use of Laboratory Animals'. Glioma cells (7.5 Â 10 6 U251MG) were subcutaneously injected into the flanks of 6-week-old male atymic CD1-nude mice (Charles River, Sulzfeld, Germany) using a 30-G needle. The tumor volumes were regularly measured using a caliper. The tumor volume was calculated using the following formula: (long axis Â short axis 2 )/2. Therapy was initiated once the tumors reached a volume of 60 mm 3 . ABT-737 was given two times a day intraperitoneally (i.p.) for a total of 2 days (150 mg/kg/day). For i.p. administration, ABT-737 was added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water), pH 4-5. Control mice were injected with the carrier substance of ABT-737 alone. The mice were killed 48 h later. Alternatively, the nude mice were intracranially injected with U251MG glioma cells as previously described in detail (Roth et al., 1999; Ahmadi et al., 2006) . Briefly, the needle of a 10 ml Hamilton syringe (Hamilton, Darmstadt, Germany) was inserted in steps of 1-2 mm per min into the brain to a depth of 4 mm at the level of the basal ganglia. For intracerebral tumor cell engraftment, cells were injected through the borehole over a time period of 5 min in steps of 1 ml/min. After injection of 1 Â 10 5 cells, the cannula was withdrawn in steps of 1-2 mm per min. Seven and 9 days after glioma cell implantation, 5 ml of a solution containing 7.5 mg/kg ABT-737 in carrier solution were stereotactically injected into the tumor in the right striatum (n ¼ 8). Control animals received 5 ml of the carrier solution injected into the tumor (n ¼ 10). The body weight and neurological symptoms were recorded daily. The mice were killed when developing neurological symptoms or weight loss exceeding 10% of the body weight. At the end of the observation period (90 days after inoculation), the surviving animals were killed and the brain subjected to histological analysis. Immunohistochemistry was performed as outlined in Supplementary Information.
